Quarterly report pursuant to Section 13 or 15(d)

Licenses Acquired - Additional Information (Detail)

v3.2.0.727
Licenses Acquired - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Apr. 28, 2015
Apr. 02, 2015
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Payments to Acquire Intangible Assets         $ 1,250,000 $ 0
Research And Development In Process     $ 1,548,000 $ 0 8,987,000 0
Stock Issued During Period, Value, Issued for Services         1,000 4,000
Research And Development Expense     $ 2,411,000 $ 2,377,000 $ 4,066,000 $ 6,865,000
Share Price     $ 9.52   $ 9.52  
Scientific Advisory Board [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Stock Issued During Period, Shares, Issued for Services         1,500,000  
Stock Issued During Period, Value, Issued for Services         $ 200,000  
Dana Farber Cancer Institute [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Marketability Percentage Of Invested Capital         44.80%  
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent         30.00%  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares         500,000  
Share Price     $ 0.065   $ 0.065  
Dana Farber Cancer Institute [Member] | Research and Development Expense [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Research And Development Expense         $ 32,500  
Collaboration Agreement with TGTX [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Payments for Fees         500,000  
Collaboration Agreement with TGTX [Member] | TG Therapeutics, Inc [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Payments for Fees     $ 0   500,000  
Agreement With City Of Hope [Member] | Mustang Bio, Inc [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Payments to Acquire in Process Research and Development         $ 2,000,000  
Restricted Stock Purchase Agreement [Member] | Dana Farber Cancer Institute [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Marketability Percentage Of Invested Capital         44.80%  
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent         30.00%  
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage         25.00%  
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period         48 months  
Share Price     $ 0.065   $ 0.065  
Stock Issued         $ 100,000  
Chief Executive Officer [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Stock Issued During Period, Shares, Issued for Services         1,000,000  
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights         grant vests 50% in four annual equal tranches of 12.5%, with the remaining 50% vesting upon the achievement of certain performance goals.  
EGFR inhibitors [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Research And Development In Process         $ 1,000,000  
IV Tramadol [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Marketability Percentage Of Invested Capital         44.80%  
Research And Development In Process [1]         $ 3,000,000  
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent         30.00%  
Share Price     $ 0.146   $ 0.146  
Checkpoint Therapeutics, Inc [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Research And Development In Process         $ 1,033,000  
Research And Development Expense     $ 9,000   12,000  
Helocyte [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Research And Development In Process         200,000  
Helocyte Biosciences Inc [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Research And Development Expense         200,000  
Licensing Agreements [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Payments to Acquire Intangible Assets $ 50,000 $ 150,000        
Licensing Agreements [Member] | NeuPharma [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Payments for Fees         $ 1,000,000  
Licensing Agreements [Member] | City Of Hope [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Marketability Percentage Of Invested Capital         0.00%  
Payments for Fees         $ 2,000,000  
Stock Issued During Period, Shares, Other         1,000,000  
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent         0.00%  
Research And Development Expense         $ 100,000  
Share Price     $ 0.147   $ 0.147  
Stock Issued During Period, Value, Other         $ 100,000  
Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Shares Issued   500,000        
Licensing Agreements [Member] | Dana Farber Cancer Institute [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Payments for Fees         $ 1,000,000  
Licensing Agreements [Member] | Dana Farber Cancer Institute [Member] | Research and Development Expense [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Stock Issued During Period, Shares, Other         500,000  
Licensing Agreements [Member] | Coronado SO [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Marketability Percentage Of Invested Capital         44.80%  
Payments for Fees         $ 900,000  
Stock Issued During Period, Shares, Other         150,000  
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent         30.00%  
Research And Development Expense         $ 1,400,000  
Share Price     $ 1.19   $ 1.19  
Stock Issued During Period, Value, Other         $ 200,000  
Licensing Agreements [Member] | Coronado SO [Member] | Scenario, Forecast [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Payments for Fees         500,000  
Licensing Agreements [Member] | IV Tramadol [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Payments to Acquire Intangible Assets         1,000,000  
Payments for Fees         2,000,000  
Licensing Agreements [Member] | Helocyte [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Stock Issued During Period, Value, Purchase of Assets         500,000  
Avenue Therapeutics, Inc. [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Stock Issued During Period, Value, Issued for Services     $ 23,000   $ 23,000  
Avenue Therapeutics, Inc. [Member] | Chief Executive Officer [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Stock Issued During Period, Shares, Issued for Services     1,000,000      
Avenue Therapeutics, Inc. [Member] | Consultants [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Stock Issued During Period, Shares, Issued for Services     150,000   150,000  
[1] The Company intends to transfer this license to Avenue.